FDA calendar · May 2023 · built from SEC filings

PDUFA dates May 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in May 2023. The FDA calendar also recorded 28 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in May 2023

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

May 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
May 1, 2023Lumryz (sodium oxybate)ALKSFDA approval—ApprovedopenFDA Drugs@FDA
May 2023Month disclosedTEPKINLY (epcoritamab)GMABFDA approval—ApprovedSEC 8-K Exhibit 99.1
May 2023Month disclosed—IBRXComplete Response Letter—CRL issuedSEC Form 10-Q
May 2023Month disclosedXACDUROINVAFDA approval—ApprovedSEC Form 10-Q
May 2023Month disclosedAmtagvi® (lifileucel)IOVANDA/BLA accepted—CompletedSEC Form 10-Q
May 2023Month disclosedVyjuvek (beremagene geperpavec)KRYSFDA approvaldystrophic epidermolysis bullosaApprovedSEC 8-K Exhibit 99.1
May 2023Month disclosedAYVAKIT® (avapritinib)SNYFDA approvaladvanced SM in June 2021 and indolent SM in May 2023ApprovedSEC 8-K Exhibit 99.1
May 2023Month disclosedOPVEE (nalmefene)SUPNFDA approval—ApprovedSEC 8-K Exhibit 99.1
May 3, 2023Kalydeco (ivacaftor)VRTXLabel expansion—ApprovedopenFDA Drugs@FDA
May 8, 2023Farxiga (dapagliflozin)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
May 11, 2023Cosentyx (secukinumab)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
May 11, 2023TAXOL® (paclitaxel)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
May 12, 2023Lexapro (escitalopram oxalate)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
May 12, 2023delandistrogene moxeparvovec with the requested indicationSRPTAdvisory committee—CompletedFDA advisory committee calendar
May 18, 2023Imbruvica (ibrutinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
May 18, 2023RINVOQ® (upadacitinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
May 18, 2023Miebo (perfluorohexyloctane)BLCOFDA approvalTo treat signs and symptoms of dry eye diseaseApprovedFDA Novel Drug Approvals
May 19, 2023Epkinly (epcoritamab-bysp)GMABFDA approval—ApprovedFDA Novel Drug Approvals
May 23, 2023durlobactamINVAFDA approval—ApprovedSEC Form 10-K
May 25, 2023PAXLOVID® (nirmatrelvir-ritonavir)PFEFDA approval—ApprovedFDA Novel Drug Approvals
May 26, 2023Zinplava (bezlotoxumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 31, 2023LYNPARZA® (olaparib)AZNLabel expansion—ApprovedopenFDA Drugs@FDA

May 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
May 2023Month disclosedcarbapenemINVATopline readoutwith carbapenem-resistant Acinetobacter infections, with positive top-line dataPositiveSEC Form 10-K
May 2023Month disclosedEvrenzo® (roxadustat)KYNBTopline readout—PositiveSEC Form 10-Q
May 2023Month discloseddenifanstat (TVB-2640)SGMTTopline readout—PositiveSEC Form 10-K
May 2023Month disclosedpegtibatinase (TVT-058)TVTXTopline readout—PositiveSEC Form 10-Q
May 2023Month disclosedVK2809VKTXTopline readout—PositiveSEC Form 10-Q

May 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
May 2023Month disclosedaleniglipron (GSBR-1290)GPCRTrial start—CompletedSEC Form 10-Q

Questions

What PDUFA dates are in May 2023?

0 PDUFA dates fell in May 2023. The FDA calendar also recorded 28 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.